Welcome on the Necker-Enfants Malades Institute website

from basic science:
to the translational research:
Guillaume Canaud


More information: please visit http://canaudlab.recherche.parisdescartes.fr

Five major original publications

  • Bayard C., Segna E., Taverne M., Fraissenon A., Hennocq Q., Periou B., Zerbib L., Ladraa S., Chapelle C., Hoguin C., Kaltenbach S., Villarese P., Asnafi V., Broissand C., Nemazanyy I., Autret G., Goudin N., Legendre C., Authier F-J, Viel T., Tavitian B., Gitiaux C., Fraitag S., Duong J-P, Delcros C., Sergent B., Picard A., Dussiot M., Guibaud L., Khonsari H., Canaud G. (2023). Hemifacial myohyperplasia is due to somatic muscular PIK3CA gain-of-function mutations and responds to pharmacological inhibition. J Exp Med. Nov 6; 220(11):e20230926. doi: 10.1084/jem.20230926. Epub 2023 Sep 15
  • Ladraa S., Zerbib L., Bayard C., Fraissenon A., Venot Q., Morin G., Garneau A.P., Isnard P., Chapelle C., Hoguin C., Fraitag S., Duong J-P., Guibaud L., Besançon A., Kaltenbach S., Villarese P., Asnafi V., Broissand C, Goudin N., Dussiot M., Nemazanyy I., Viel T., Autret G., Cruciani-Guglielmacci C., Denom J., Bruneau J., Tavitian B., Legendre C., Dairou J., Lacorte J-M., Levy P., Pende M., Polak M., Canaud G. (2022). PIK3CA gain-of-function mutation in adipose tissue induces metabolic reprogramming with Warburg-like effect and severe endocrine disruption. Sci Adv. Dec 9;8(49):eade7823. doi: 10.1126/sciadv.ade7823. Epub 2022 Dec 9.
  • Delestre F., Venot Q., Bayard C., Fraissenon A., Ladraa S., Hoguin C., Chapelle C., Yamaguchi J., Cassaca R., Zerbib L., Magassa S., Morin G., Asnafi V., Villarese P., Kaltenbach S., Fraitag S., Duong J-P, Broissand C., Boccara O., Soupre V., Bonnotte B., Chopinet C., Mirault T., Legendre C., Guibaud L., Canaud G. (2021). Alpelisib administration reduced lymphatic malformations in a mouse model and in patients. Sci Transl Med. Oct 6;13(614):eabg0809. doi: 10.1126/scitranslmed.abg0809. Epub 2021 Oct 6.
  • Venot Q., Blanc T., Hadj Rabia S., Berteloot L., Ladraa S., Duong J-P., Blanc E., Johnson S.C., Hoguin C., Boccara O., Sarnacki S., Boddaert N., Pannier S., Martinez F., Magassa S., Yamaguchi J., Knebelmann B., Merville P., Grenier N., Joly D., Cormier-Daire V., Michot C., Bole-Feysot C., Picard A., Soupre V., Lyonnet S., Sadoine J., Slimani L., Chaussain C., Laroche-Raynaud C., Guibaud L., Broissand C., Amiel J., Legendre L., Terzi F., Canaud G. (2018). Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. Jun;558(7711):540-546 with commentary Jun;558(7711):523-526. doi: 10.1038/s41586-018-0217-9.
  • Canaud G., Bienaimé F., Tabarin F., Bataillon G., Seilhean D., Noel L.H., Dragon-Durey M.A., Snanoudj R., Friedlander G., Halbwachs-Mecarelli L., Legendre C., Terzi F. (2014). Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome. N Engl J Med. Jul 24;371(4):303-12. doi: 10.1056/NEJMoa1312890. with commentary 2014 Oct 16;371(16):1554-5. doi:10.1056/NEJMc1410247.
  • List of publications


  • Isnard P, Kula T, Avettand Fenoel V, Anglicheau D, Terzi F, Legendre C, Elledge S, Canaud G.
    Temporal virus serological profiling of kidney graft recipients using VirScan.
    Proc Natl Acad Sci USA. 2019 May 13
  • Canaud G, Brooks CR, Kishi S, Taguchi K, Nishimura K, Magassa S, Scott A, Hsiao LL, Ichimura T, Terzi F, Yang L and Bonventre JV.
    Cyclin G1 and TASCC regulate pro-fibrotic secretory phenotypes in kidney tubule cells in the G2/M phase of the cell cycle.
    Sci Transl Med. 2019 Jan 23;11(476)
  • Johnson SC, Martinez F, Bitto A, Gonzalez B, Tazaerslan C, Cohen C, Delaval L, Timsit J, Knebelmann B, Terzi F, Mahal T, Zhu Y, Morgan PG, Sedensky MM, Kaeberlein M, Legendre C, Suh Y, Canaud G.
    mTOR inhibition Attenuates Human Mitochondrial Encephalopathy with Lactic Acidosis and Stroke-like Episodes (MELAS).
    Kidney Int. 2019 Feb;95(2):455-466
  • 2018

  • Venot Q, Blanc T, Hadj Rabia S, Berteloot L, Ladraa S, Duong JP, Blanc E, Johnson SC, Hoguin C, Boccara O, Sarnacki S, Boddaert N, Pannier S, Martinez F, Magassa S, Yamaguchi J, Knebelmann B, Merville P, Grenier N, Joly D, Cormier-Daire V, Michot C, Bole-Feysot C, Picard A, Soupre V, Lyonnet S, Sadoine J, Slimani L, Chaussain C, Laroche-Raynaud C, Guibaud L, Broissand C, Amiel, Legendre L, Terzi F, Canaud G.
    Targeted therapy in patients with PIK3CA-related overgrowth syndrome.
    Nature 2018 Jun;558(7711):540-546 with commentary Jun;558(7711):523-526
  • 2016

  • Delville M, Baye E, Durrbach A, Audard V, Kofman T, Braun L, Olagne J, Nguyen C, Deschênes G, Moulin B, Delahousse M, Kesler-Roussey G, Beaudreuil S, Martinez F, Rabant M, Grimbert P, Gallazzini M, Terzi F, Legendre C, Canaud G.
    Costimulation (B7-1) blockade does not improve post transplant nephrotic syndrome from recurrent FSGS.
    J Am Soc Nephrol. 2016 Aug;27(8):2520-7
  • 2014

  • Canaud G, Bienaimé F, Tabarin F, Bataillon G, Seilhean D, Noel LH, Dragon-Durey MA, Snanoudj R, Friedlander G, Halbwachs-Mecarelli L, Legendre C, Terzi F.
    Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome.
    N Engl J Med. 2014 Jul 24;371(4):303-312, with commentary Jul 24;371(4):369-371
  • Canaud G, Dejucq-Rainsford N, Avettand-Fenoël V, Viard JP, Anglicheau D, Bienaimé F, Muorah M, Galmiche L, Gribouval O, Noël LH, Satie AP, Martinez F, Sberro-Soussan R, Scemla A, Gubler MC, Friedlander G, Antignac C, Onetti Muda A, Terzi F, Rouzioux C, Legendre C.
    The kidney as a reservoir for HIV-1 after renal transplantation.
    J Am Soc Nephrol. 2014 Feb;25(2):407-19, with commentary Feb;25(2):212-5
  • 2013

  • Canaud G, Bienaimé F, Treins C, Viau A, Nguyen C, Berissi S, Giannakakis K, Muda Onetti A, Friedlander G, Legendre C, Pende M, Terzi F.
    Stress-induced Akt2 activation is crucial for podocyte maintenance in chronic kidney disease.
    Nat Med. 2013 Oct;19(10):1288-96, with commentary Oct;19(10):1212-3

  • More information: https://www.ncbi.nlm.nih.gov/pubmed/?term=canaud+g

    Our group is dedicated to decipher the mechanisms underlying the physiopathology of overgrowth syndromes (PROS) in order to improve patient’s condition. We have been working since a long time on the PIK3/AKT/mTOR pathway in the context of kidney diseases but based on a patient experience, we have progressively moved to this new field in 2016.

    In order to achieve our goal, we have 2 sides: the research laboratory and the clinic. Very importantly, we have a very strong interaction between these two entities.

    The laboratory (http://canaudlab.recherche.parisdescartes.fr) is developing new in vitro and in vivo models to better understand disease progression, to identify potential biomarkers and to offer new therapeutic opportunities. To this end, we have engineered multiple genetic mouse models and we are using innovative technology to explore the molecular and structural cellular changes in overgrowth syndromes. Currently, we are trying to understand the impact of PIK3CA mutation on the fate of the different tissues (adipose tissues, bones, vessels…). To support our research, we are lucky enough to have multiple findings including European (ERCs) and Governmental grants but also from private and public Foundation supports and generous donators (i.e. US Cloves community syndrome).

    From the clinical perspective (http://www.maladiesrares-necker.aphp.fr/syndromes-dhypercroissance/), we have created a unit dedicated to patient with overgrowth syndromes. We offer state of the art genotyping and the patients have access on single day to all the specialists (surgeons, geneticists, radiologists, dermatologist, endocrinologists…). This team also includes administrative assistants to organize all the medical appointments, nurses, assistant nurses, physical therapists, psychologists… We just received a EUR 10 Million grant from our Government to accelerate our development. We are seeing French but also patients coming from abroad. Every month, we have a multidisciplinary meeting to discuss all new cases as well as patients necessitating specific advices.

    This is a very exciting Human adventure and if you want to join or visit us do not hesitate to contact me.

    Permanent researcher
    Guillaume Canaud
    Professor Researcher
    +33 (0)1 40 61 54 25
    Permanent engineer
    Charles Bayard
    +33 (0)1 40 61 54 28
    Clément Hoguin
    +33 (0)1 40 61 54 28
    Sophia Ladraa
    +33 (0)1 40 61 54 85
    Hamida Makouf
    Financial Administrative
    +33(0)1 40 61 54 85
    Sanela Protic
    Assistant in Biological Techniques
    Junna Yamaguchi
    +33 (0)1 40 61 54 28
    Non permanent engineer
    Rubina Dias Cassaca
    +33 (0)1 40 61 54 28
    Franck Mayeux
    Post-doctoral degree
    Alexandre Garneau
    Post-Doctoral Researcher
    +33 (0)1 40 61 54 28
    Pranavi Amuda Ravichandar
    PhD Student
    Sandro Benichi
    PhD Student
    Ilaria Galasso
    PhD Student
    +33 (0)1 40 61 54 28
    Gabriel Morin
    +33 (0)1 40 61 54 28

    Notice: Undefined variable: contact_addr in /homepages/40/d483507699/htdocs/location.php on line 21
    HRH Princess Caroline of Hanover, who through the Princess Grace Foundation, already supports medical research and anything that helps to relieve the sick children in France and around the world, has agreed to commit to our side so that our Center of Molecular medicine continues to meet the current challenges and fight diseases, and in particular the ones affecting children.

    INEM - Organigramme